Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19-Reference-Cited by-同舟云学术

Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

Published:2022-04-06 Issue:6 Volume:111 Page:1324-1333
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Hong Eunjin¹,Almond Lisa M.²,Chung Peter S.³⁴,Rao Adupa P.³⁴,Beringer Paul M.¹⁴

Affiliation:

1. Department of Clinical Pharmacy School of Pharmacy University of Southern California Los Angeles California USA

2. Simcyp Division Certara UK Ltd Sheffield UK

3. Division of Pulmonary and Critical Care Medicine Department of Medicine Keck School of Medicine University of Southern California Los Angeles California USA

4. University of Southern California, Anton Yelchin Cystic Fibrosis Clinic Los Angeles California USA

Funder

Cystic Fibrosis Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2585

Reference30 articles.

1. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

2. Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor